Fecal Microbiota Transplantation (FMT) for C
Total Page:16
File Type:pdf, Size:1020Kb
Fecal Microbiota Transplantation (FMT) For C. difficile Infection (CDI) in Solid Organ Transplant (SOT) Recipients Protocol Number: 2018-1056 National Clinical Trial (NCT) Identified Number: NCT03617445 Principal Investigator & IND Sponsor: Nasia Safdar, MD, PhD Funded by: NIAID Version Number: 5 Date: 05 January 2021 This document is confidential. No part of it may be transmitted, reproduced, published, or used by other persons without prior written authorization from the Sponsor or Principal Investigator. RECOVER PI: N. Safdar PROTOCOL VERSION HISTORY Version Date Comment 1.0 13AUG2018 Initial version 1.1 29AUG2018 Amendment per FDA 2.0 24Jul2019 Amendment per FDA and Steering Committee 3.0 12Mar2020 Amendment 4.0 24Aug2020 Amendment 5.0 05Jan2021 Amendment – FMT route of administration Version 5 05 January 2021 Page 2 of 86 RECOVER PI: N. Safdar TABLE OF CONTENTS 1.0 STATEMENT OF COMPLIANCE .............................................................................................................5 2.0 LIST OF ABBREVIATIONS .....................................................................................................................6 3.0 TERMINOLOGY .......................................................................................................................................7 4.0 STUDY SUMMARY ..................................................................................................................................7 Schematic of Study Design ........................................................................................................................... 9 5.0 KEY PERSONNEL .................................................................................................................................10 6.0 INTRODUCTION ....................................................................................................................................12 Background ................................................................................................................................................. 12 Rationale ..................................................................................................................................................... 12 7.0 STUDY OBJECTIVES AND ENDPOINTS .............................................................................................14 Primary Objective ........................................................................................................................................ 14 Secondary Objectives ................................................................................................................................. 14 Primary Outcome Measure ......................................................................................................................... 16 Secondary Outcome Measures .................................................................................................................. 16 8.0 STUDY DESIGN .....................................................................................................................................20 General Design ........................................................................................................................................... 20 Rationale for Intervention ............................................................................................................................ 20 Study Risk/Benefit Assessment .................................................................................................................. 21 End of Study Definition................................................................................................................................ 22 9.0 SUBJECT SELECTION ..........................................................................................................................23 Inclusion/Exclusion Criteria ......................................................................................................................... 23 Recruitment ................................................................................................................................................. 24 Retention Strategies .................................................................................................................................... 24 Early Termination and Withdrawal .............................................................................................................. 24 10.0 STUDY INTERVENTION ........................................................................................................................25 Study Intervention Description .................................................................................................................... 25 Source ......................................................................................................................................................... 25 Packaging and Labeling .............................................................................................................................. 26 Preparation .................................................................................................................................................. 27 Storage and Stability ................................................................................................................................... 27 Accountability .............................................................................................................................................. 27 Dosing and Administration .......................................................................................................................... 28 Randomization and Blinding ....................................................................................................................... 28 Unblinding Procedures ................................................................................................................................ 28 Study Intervention Compliance ................................................................................................................... 28 Concomitant Therapy .................................................................................................................................. 29 11.0 STUDY VISITS AND PROCEDURES ....................................................................................................29 Screening and Enrollment ........................................................................................................................... 29 Visit 1 (Baseline) ......................................................................................................................................... 30 Visit 2 (Randomization) ............................................................................................................................... 30 Study Drug Administration Follow-up Call .................................................................................................. 31 Visit 3 (in-person) ........................................................................................................................................ 31 Visit 4 (in-person or phone call) .................................................................................................................. 31 Visit 5 (in-person or phone call) .................................................................................................................. 31 Version 5 05 January 2021 Page 3 of 86 RECOVER PI: N. Safdar Visit 6 (in-person or phone call) .................................................................................................................. 31 Visit 7 (in-person or phone call) .................................................................................................................. 32 Telephone Contact ...................................................................................................................................... 32 Unscheduled Visit ....................................................................................................................................... 32 Early Termination and Withdrawal .............................................................................................................. 32 Study Calendar ........................................................................................................................................... 34 Study Procedures ........................................................................................................................................ 36 12.0 DATA COLLECTION, HANDLING AND RECORD KEEPING ..............................................................38 Types of Data .............................................................................................................................................. 38 Data Collection ............................................................................................................................................ 38 Data Capture Methods ................................................................................................................................ 39 Data Confidentiality ..................................................................................................................................... 40 Records Retention .....................................................................................................................................